|
Prostatic bladder neck obstruction(BNO) or benign prostatic hyperplasia (BPH) rarely causes symptoms before
the age of 40 years. However, symptoms occur due to BNO in more than half of men in their sixties, and up to 90% of men in their seventies and
eighties. Management of this condition includes issues relating to exclusion of prostate cancer, timing of intervention, and type of intervention most suitable for the individual patient.
Symptoms of BNO are best considered
as being either obstructive or irritative.
Obstructive symptoms include a poor
pressure flow, hesitancy and a sense of
incomplete emptying. Irritative symptoms
include frequency, urgency, urge
incontinence and nocturia.
It is frequently the irritative symptoms
that so adversely affect the quality
of life of men. For example, the need
to void four or five times per night
causes chronic tiredness and lethargy.
Men with BNO are at increased risk
of urinary tract infection. Older men
who suffer urinary tract infection
should be urodynamically investigated
for underlying obstructive bladder
dysfunction.
Unlike female cystitis, appropriate
antibiotics should be provided for a full
three weeks, as bacterial infection of
the prostate is deep-seated. Short-
course antibiotics may cause septic
rebound.
End-stage BNO results in acute
urinary retention, which is very painful
and obvious. Slow onset chronic urin
ary retention is, in fact, bladder
muscle failure. Chronic large residual
volumes exist within the bladder.
Hydro-ureteronephrosis develops with
chronic renal failure if left untreated.
Formation of bladder stones also
complicates chronic outflow obstruction
(see figure 3).
Accurate diagnosis is critical
prior to management strategies
being implemented. In clinical
practice, video urodynamics is
the best means of obtaining
objective information.
A urodynamic study is a halfhour
computerised x-ray study
that involves the passage of a
small computer probe through
the urethra into the bladder. A
pressure line is also inserted per
rectum.
Both filling and voiding
profiles are studied, with voided
urinary flow correlated to bladder
pressure as measured in
centimetres of water pressure
units. During voiding, fluoroscopy
enables observation of
bladder neck and prostatic urethral
relaxation or obstruction.
Prostate symptoms scores have
been developed, but these are
used more widely in
pharmaceutical research than in
clinical practice.
As BNO is a dynamic
process, and as it does not relate
to prostatic size, the decision to
treat and especially to operate
on a man with symptoms is not
based on the size of the prostate
as determined by digital rectal
examination. Nor should it be
based on findings at cystoscopy.
The relevance of prostatic
size is to determine whether
a patient is suitable for
t r a n s u rethral resection of the
prostate or alternatively an
open or suprapubic prostat-
ectomy approach for his benign
disease.

Figure 2. Uroflowmetry results. Obstructed flow
due to BPH.
Many men present clinically
concerned that their symptoms
of benign prostatic BNO may
be indicative of early prostate
cancer.
They should be reassured
that early prostate cancer does
not cause symptoms of bladder
dysfunction.
The decision to investigate
and treat should be based on the
inconvenience of symptoms
rather than the fear that
prostate cancer may be present.
Each man who presents with
symptoms of BNO should
be evaluated individually for
prostate cancer by means of a
digital rectal examination
and prostate-specific antigen
(PSA) with free to total ratio
determination.
Men with bothersome symptoms
of BNO should be
referred. Any man with a complication
of BNO such as urinary
tract infection or bladder
stone formation should be
evaluated urologically.
All men with an elevated
PSA or abnormal digital
rectal examination should be
referred.
Fig 3. Bladder Stones
Fig 4. Lateral Lobes BPH
Men with non-bothersome early
symptoms of BNO may be
managed expectantly. Mild
symptoms do not need intervention
and occasionally improve
over time. Alternatively, however,
many men live with disruptive
urinary symptoms as
they are fearful of treatments
they do not completely understand.
It is necessary to strike a
balance between over- and
under-treating BNO.
Selective alpha-blockers such as
prazosin (Minipress) and tamsulosin
(Flomax) are able to
relieve symptoms incompletely
in 60-65% of patients.
S i d e - e ffects include postural
hypotension, nasal congestion
and retrograde ejaculation due
to relaxation of the bladder
neck sphincter. Many men are
not accepting of long-term
alpha blockade as management
for their symptoms.
Finasteride (Proscar) is a five
alpha-reductase inhibitor. It
works by inhibiting the production
of the male hormone
dihydrotestosterone, which is
thought to be responsible for
prostatic enlargement. It is of
limited therapeutic benefit.
In prostate glands greater
than 60 g, it may reduce the
incidence of acute urinary retention.
In a recent trial of prostate
cancer prevention, finasteride
was found to decrease the number
of men contracting prostate
cancer. However, those men
who were diagnosed with
prostate cancer whilst taking
finasteride were found to have
high-grade disease.
Drugs containing pseudoephedrine
will exacerbate symptoms
in men with BNO.
Pseudoephedrine has a sympathomimetic
effect on the prostatic
alpha-receptors, causing
constriction and thereby
i n c reasing outflow resistance.
Similarly, men with high-grade
BNO and secondary detrusor
(bladder muscle) instability
should not be treated with anticholinergic
medications such as
oxybutynin (Ditropan).
The effect of anticholinergic
medication in such patients is to
diminish detrusor contractility,
which results in urinary retention
when significant outflow
resistance is present.
So-called ‘alternative’ therapies
for BNO have insinuated themselves
into popular culture
during the past two decades.
They re p resent a huge worldwide
market despite the
absence of convincing placeboc
o n t rolled trials.
An article from the Journal
of Urology (J Urol 2002;
168:150-154) showed a
marked variability in dosage of
saw palmetto between manuf
acturers, and even between
individual lots from the same
manufacturer. Dosages ranged
between 97% and 140% of the
stated dose.
Takers of complementary
therapies believe in them as an
article of faith, and often claim
relief of symptoms attributable
to the substance after very short
periods of consumption.
This indicates a significant
placebo eff e c t .
A number of alternative technologies
have been marketed
during the past 15 years.
These include transurethral
needle ablation of the prostate,
prostatic alcohol injection, prostatic
thermotherapy and a
multitude of prostatic laser
therapies.
These therapies have not
gained widespread application
because of their expense and, in
many cases, lack of long-term
efficacy.
Holmium laser ablation of
the prostate is an efficacious
t reatment, but no more so than
s t a n d a rd transurethral pro s t at
ectomy, and it is associated
with significant capital expense
and re c u rring disposable costs.

Figure 5. Bladder trabeculation in
response to chronic BNO.

Fig 6. TURP. Resection loop at
bladder neck.
Small tight prostates are best
managed by bladder neck incisional
surgery rather than formal
resection of prostatic tissue.
Bladder neck incisional surg
ery involves an endoscopic
procedure under general anaesthetic;
the trigone, bladder neck
and prostate gland are incised
deeply in the midline to the level
of the verumontanum.
This relieves the obstructive
effect of the prostate on the
bladder neck and prostatic
urethra.
This is a minimal procedure
with good long-term relief of
symptoms for well-selected
patients. Bladder neck dyssynergia
occurs in men in their thirties
and forties, and is due to
spasticity of the bladder neck
mechanism.
These men have obstructive
and irritative symptoms similar
to those in older men with BPH.
The diagnosis is made by urodynamic
evaluation.
This also excludes the presence
of a urethral stricture.
Younger men with bladder
neck dyssynergia may elect to
watchfully wait or undergo
alpha blockade or bladder neck
incisional surgery. The surgery
involves a 25% occurrence of
retrograde ejaculation and,
hence, subfertility.
Bladder neck incision surgery
should not be performed on a
man who wishes to retain
fertility.

Figure 7. Resection to capsule.

Fig 8. Roller ball haemostasis.
bladder neck.
Very large benign prostates
causing significant BNO may
need to be resected via an
open suprapubic approach. An
assessment is made under an
anaesthetic with cystourethroscopy
as to the size of
the transition zone.
When it is estimated that an
endoscopic resection would
involve the removal of in excess
of 60-80 g, an open procedure is
best considered under the same
anaesthetic. Open or suprapubic
prostatectomy is the enucleation
of the transition zone
via a lower abdominal, horizontal
skin incision.
The bladder is opened and
the enucleation occurs by means
of resection through the urethra
and the removal of the transition
zone. Bladder stones can
also be removed at the time of
open prostatectomy. Patients
are usually hospitalised for four
days. They are discharged with
an indwelling catheter and leg
bag for one week.
Suprapubic prostatectomy
should not be confused with
radical retropubic prostatec-
tomy, which is an operation
performed for early prostate
cancer.
Radical prostatectomy for
early prostate cancer involves
total removal of the prostate
and its capsule. Via the suprapubic
approach, only the transition
zone is removed; the
posterior or peripheral zone of
the prostate remains in place.
Patients who have suprapubic
prostatectomy should
therefore have ongoing screening
for prostate cancer.
Unlike radical prostatectomy,
the neurovascular bundles that
s u b s e rve erectile function are
not at risk. Retrograde ejaculation
will occur after suprapubic
prostatectomy.
Holmium laser resection of very
large benign prostate glands is
also an option. Via a modified
endoscope a Holmium laser
fibre is passed into the prostatic
urethra and is used to resect
large glands with minimum
blood loss.
The difficulty with holmium
laser resection is that large
pieces of benign prostate tissue
are released into the bladder.
The removal of bulky tissue can
be difficult, which requires an
extended period of urethral
instrumentation.
Morcellation (grinding) devices
are under investigation.
Their purpose is to mince large
benign fragments of prostate
within the bladder, and thus
facilitate their removal.

Figure 9. Relief of obstruction prostatic cavity.

Fig 10. Prostate Chips
The sub-committee of the
American Urological Association
that recently reviewed
this matter considers contemporary
transurethral resection of
the prostate (TURP) to be the
gold-standard therapy for prostatic
BNO.
Contemporary TURP refers
to the operation being performed
by well-trained specialist
urological surgeons using
continuous flow resectoscopes
and three chip digital cameras
(see figures 4-10).
On average, a patient is
admitted for 48 hours and has
the procedure performed under
a spinal anaesthetic. Return to
sedentary work within five days
is feasible.
The incidence of sphincter
weakness urinary incontinence
is very low when an experienced
surgeon perf o rms the proced
u re. Vi g o rous post-operative
pelvic floor training should be
performed by men with mild to
moderate post-operative stress
incontinence. The incidence of
blood transfusions is now very
low. Improved haemostasis is
possible using modern diathermic
technology with current
spray capability.
The TURP syndrome is now
an uncommon occurrence during
endoscopic prostatic resection.
This syndrome refers to
the excess absorption of glycine
irrigating fluid during the operation,
usually via large prostatic
venous plexuses.
This syndrome may cause
c a rdiovascular and electro l y t e
disturbances during the intraoperative
and immediate postoperative
period. It is more
likely to occur when very large
prostate glands are subject to
endoscopic resection. Management
strategies include cardiovascular
support and correction
of electrolyte disturbances.
C o n t e m p o r a ry transure t h r a l
prostatectomy is now a lowmorbidity
procedure.
Following relief of prostatic
obstruction, the patient experiences
an immediate impro v ement
in urinary flow, but
irritative symptoms such as
frequency, urgency and nocturia
may take three, and on occasion,
six months to settle.
The resolution of these symptoms
depends on the degree
of pre-operative detrusor instability
that developed secondary
to the chronic outflow obstruction.
Occasionally, anticholinergic
medications such as oxybutynin
are necessary for a varying
period of time. Fifteen per cent
of men with chronic detrusor
instability prior to surgery
continue to have symptoms
post-operatively and may
require chronic oxybutynin
medication. Their obstructive
symptoms, however, will have
been relieved.
Transurethral prostatectomy
does not cause erectile dysfunction,
as it is not associated with
damage to the neurovascular
complex that proceeds to the
erectile bodies.
Retrograde ejaculation is
inevitable and men should be
warned of this event. Men still
have a normal feeling of
orgasm; ejaculatory fluid is
passed with the first post-ejaculatory
void.
TURP removes the periurethral
adenoma, now called
the transition zone of the
p rostate. It does not protect
from prostate cancer and men
should continue to have a digital
rectal examination and PSA
determination on an annual
basis.
Prostatic BNO is a common
condition in men aged 50 years
and over, and it adversely
affects quality of life. Accurate
diagnosis and judicious treatment
will result in a good
clinical outcome.
|
|